Clinical trial NCT02881242: Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer
Official title: A Single-Arm, Open-Label, Two-Stage Phase II Study of the MEK 1/2 Inhibitor Trametinib in Men With Progressive Metastatic Castrate Resistant Prostate Cancer
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE2
Conditions: Hormone-Resistant Prostate Cancer
Metastatic Prostate Carcinoma
Recurrent Prostate Carcinoma
Stage IV Prostate Cancer
Lead sponsor: Jonsson Comprehensive Cancer Center
Sponsor class: OTHER
Collaborators: name: Stand Up To Cancer
name: Novartis
name: Prostate Cancer Foundation
First posted: 2016-08-26
Enrollment: 14
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This phase II trial studies how well trametinib works in treating patients with hormone-resistant prostate cancer that is growing or getting worse and has spread to other parts of the body. Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Detailed description: PRIMARY OBJECTIVES I. To assess the activity of trametinib in metastatic castration resistant prostate cancer (mCRPC) that has progressed on either enzalutamide or abiraterone acetate.

SECONDARY OBJECTIVES I. Durability of prostate specific antigen (PSA) response as measured by the time to PSA progression as defined by Prostate Cancer Working Group 2 guidelines for PSA progression.

II. Maximal PSA response. III. Quality of life by Functional Assessment of Cancer Therapy- Prostate (FACT-P).

IV. Time to initiation of alternative antineoplastic therapy. V. Time to radiographic progression. VI. Objective response rate according to Response Evaluation Criteria in Solid Tumors (RECIST) guidelines.

VII. Overall survival measured as time from enrollment until death. VIII. Safety and tolerability. IX. Analysis of trametinib target engagement of mitogen-activated extracellular signal-related kinase (MEK1/2) is assessed by presence of p-ERK, the primary phosphorylation target of activated MEK1/2, in pre-treatment and at progression radiographically directed metastatic tumor biopsies by immunohistochemistry evaluation of p-ERK. Markers of cell proliferation (Ki67) and apoptosis (p27) will also be assessed.

XI. Investigation of molecular correlates to resistance and sensitivity to trametinib using pre-treatment and at progression metastatic biopsies.

XII. Discovery of one or a set of possible discriminative networks that are associated with a response to trametinib.

XII. Enrichment for patients in the second phase who have tumors exhibiting genomic features associated with a response to trametinib.

XIV. Analyses of circulating tumor deoxyribonucleic acid (ctDNA) for genomic aberrations correlated to treatment response.

OUTLINE:

Patients receive trametinib orally (PO) once daily (QD). Treatment continues in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 2 and 4 weeks, and then every 4 weeks thereafter.

Eligibility criteria: Inclusion Criteria:

* Willing and able to give informed consent
* Histologically confirmed prostate cancer (not exclusive of adenocarcinoma)
* mCRPC that has progressed on at least 1 therapy progression (defined as Prostate Cancer Working Group 2 \[PCWG2\] or at investigators' discretion) approved for treatment of mCRPC, one of which must include abiraterone acetate and/or enzalutamide
* Metastatic tumor that has been biopsied
* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
* Willing to undergo biopsy of a metastatic lesion at the time of progression
* Patients must have ongoing therapy to maintain serum testosterone \< 50 ng/dL
* Absolute neutrophil count \> 1,500/uL during screening evaluation
* Platelet count \> 100,000/uL during screening evaluation
* Hemoglobin \> 9 g/dL during screening evaluation
* Total bilirubin within the reference range during screening evaluation
* Alanine aminotransferase (ALT) within the reference range during screening evaluation
* Aspartate aminotransferase (AST) within the reference range during screening evaluation
* Creatinine \< (1.5 mg/dL) during screening evaluation (\> 1.5 is allowed if epidermal growth factor receptor \[EGFR\] \> 45 mL/min/1.73 m\^2)
* International normalized ratio (INR) \< 1.3 (or \< 3 if on warfarin or other anticoagulants) during screening evaluation
* Left ventricular ejection fraction (LVEF) \>= 45% as measured by echocardiogram during screening evaluation
* Electrocardiogram (EKG) without clinically significant abnormality

Exclusion Criteria:

* A history of retinal vein occlusion (RVO) or risks factors for RVO
* A history of retinal pigment epithelial detachment (RPED) or risk factors for RPED
* Clinically significant abnormality on ophthalmologic examination during screening evaluation
* Clinically significant cardiovascular disease including:

  * LVEF \< 45% measured by echocardiogram
  * History of acute coronary syndromes (including myocardial infarction and unstable angina), coronary angioplasty, or stenting within 6 months
  * Uncontrolled angina within 3 months
  * New York Heart Association (NYHA) class III or IV congestive heart failure
  * Clinically significant abnormality on EKG
  * History of clinically significant ventricular arrhythmias (e.g., ventricular tachycardia, ventricular fibrillation, torsades de pointes)
  * Patients with intra-cardiac defibrillators or permanent pacemakers
* Presence of a comorbid disease or medical condition that would impair the ability of the patient to receive or comply with the study protocol
* History of interstitial lung disease or pneumonitis
* Use of any medication or herbal products that may have hormonal anti-prostate cancer activity and/or are known to modulate PSA levels (e.g., saw palmetto) or systemic corticosteroids greater than the equivalent of 10 mg of prednisone per day within 4 weeks of enrollment
* Prior use of trametinib or other mitogen activated protein kinase (MAPK) inhibitor in any context
* Known or suspected brain metastasis or active leptomeningeal disease or spinal cord compression
* Gastrointestinal disorder affecting absorption (e.g., gastrectomy, active peptic ulcer disease within last 3 months, inflammatory bowel disease)
* Any major surgery, extensive radiotherapy, chemotherapy with delayed toxicity, biologic therapy, or immunotherapy within 30 days of enrollment and/or daily or weekly chemotherapy without the potential for delayed toxicity within 14 days of enrollment
* Hospitalization within 30 days of enrollment for cancer related events
* History of another malignancy within the previous 5 years other than curatively treated non-melanoma skin cancer
* Use of an investigational agent within 4 weeks of enrollment
* Use of any medications known to affect the serum androgen level
* Any condition or reason that, in the opinion of the investigator, interferes with the ability of the patient to participate in the trial, which places the patient at undue risk, or complicates the interpretation of safety data

Primary outcomes:
measure: PSA response rate
timeFrame: At 12 weeks
measure: Response rate assessed by RECIST criteria
timeFrame: Up to 24 weeks
Secondary outcomes:
measure: Change in markers of cell proliferation (Ki67) and apoptosis (p27), assessed by immunohistochemistry
timeFrame: Baseline up to 24 weeks
measure: Change in trametinib target engagement of MEK1/2 defined by the presence of p-ERK, assessed by immunohistochemistry
timeFrame: Baseline up to 24 weeks
measure: Durability of PSA response as measured by time to PSA progression as defined by PCWG2 guidelines
timeFrame: Up to 30 months
measure: Incidence of adverse events, graded according to the Common Terminology Criteria for Adverse Events version 4.0
timeFrame: Up to 30 months
measure: Maximal PSA response
timeFrame: Up to 30 months
measure: Molecular correlates defined by gene expression, assessed using ribonucleic acid-sequencing, and mutational events, assessed using DNA exome-seq
timeFrame: Up to 24 weeks
measure: Objective radiographic response rate according to RECIST guidelines
timeFrame: Up to 24 weeks
measure: Overall survival
timeFrame: Time from enrollment until death, assessed for up to 30 months
measure: Quality of life, assessed by FACT-P
timeFrame: Up to 30 months
measure: Time to initiation of alternative anti-neoplastic therapy
timeFrame: Up to 30 months
measure: Time to radiographic progression
timeFrame: Up to 24 weeks
Other outcomes:
measure: ctDNA genomic aberrations, assessed by exome sequencing
timeFrame: Up to 24 weeks
Locations:
city: Los Angeles
country: United States
facility: UCLA / Jonsson Comprehensive Cancer Center
state: California
Study officials:
affiliation: UCLA / Jonsson Comprehensive Cancer Center
name: Matthew Rettig
role: PRINCIPAL_INVESTIGATOR
References: